Cigna Group 8-K, filed May 1, 2023
Cigna Group (CI)
About this 8-K
Cigna Group filed this 8-K on May 1, 2023, reporting on events of April 26, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:
(860)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 26, 2023, the board of directors (the “Board”) of The Cigna Group (the “Company” or “our”) appointed Dr. Philip Ozuah as an independent member of our Board and to the People Resources and Compliance Committees, which appointments are effective June 1, 2023.
Dr. Ozuah will participate in the Company’s non-employee director compensation program, amended and restated effective April 1, 2022 (the “Plan”), as described in our Proxy Statement for the 2023 Annual Meeting of Shareholders, filed with the Securities and Exchange Commission (the “SEC”) on March 17, 2023. A copy of the Plan has been filed as Exhibit 10.16(b) to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 23, 2023.
There is no arrangement or understanding between Dr. Ozuah and any other person pursuant to which Dr. Ozuah was selected as a director. There have been no transactions involving Dr. Ozuah that would be required to be disclosed by Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended.
A copy of the Company’s press release announcing the appointment of Dr. Ozuah is attached to this report as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit No. | Description |
| 99.1 | Press release dated May 1, 2023 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| THE CIGNA GROUP | ||
| Date: May 1, 2023 | By: | /s/ Nicole S. Jones |
| Nicole S. Jones | ||
| Executive Vice President and General Counsel | ||
Exhibit 99.1
| Press Release |  |
The Cigna Group Announces Appointment of Dr. Philip Ozuah to Board of Directors
BLOOMFIELD, Conn., May 1, 2023 – Global health company The Cigna Group (NYSE:CI) today announced that Dr. Philip Ozuah has been appointed to the organization’s Board of Directors. His appointment is effective June 1, 2023.
Since 2019, Dr. Philip Ozuah has served as the President and CEO of Montefiore Medicine, the umbrella organization for the Albert Einstein College of Medicine and Montefiore Health System’s 13 member hospitals and 300 ambulatory sites. Dr. Ozuah has spent 32 years at Montefiore Medicine in positions of increasing responsibility, including as President of Montefiore Health System from 2018 to 2019, as well as Executive Vice President and Chief Operating Officer from 2012 to 2018. Under his guidance, Montefiore Medicine has built a strong national reputation as a leader in value-based care with an emphasis on aligning community-based organizations and services critical to addressing the socioeconomic determinants of health.
"We are pleased to welcome Phil as a new independent director to our Board," said David M. Cordani, The Cigna Group chairman and chief executive officer. "His dedication to medicine, expertise in effective value-based care, and commitment to making health care more accessible will be tremendously important to The Cigna Group as we work to deepen our relationships with physician partners and improve the health and vitality of all of those we serve."
Dr. Ozuah joins our Board with deep expertise and a diverse background. Over the past five years, more than 60% of The Cigna Group Board has been refreshed to ensure diversity of skillset, experience and views. In 2022, the Board composition was above average compared to S&P benchmarks on median age, tenure, gender and ethnic diversity.
“We are proud of our Board’s deep and long-held commitment to strong governance, as well as ethical and resilient business practices. The appointment of Phil underscores the high bar we hold ourselves to in terms of talent and leadership,” continued Cordani.
About The Cigna Group
The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has more than 190 million customer relationships around the world. Learn more at thecignagroup.com.
Media Contact
Meaghan MacDonald
1 (860) 840-1212
meaghan.macdonald@cigna.com